` 128940 (Hanmi Pharm Co Ltd) vs KOSPI 200 Comparison - Alpha Spread

128940
vs
K
KOSPI 200

Over the past 12 months, Hanmi Pharm Co Ltd has underperformed KOSPI 200, delivering a return of +62% compared to the KOSPI 200's +81% growth.

Stocks Performance
128940 vs KOSPI 200

Loading
128940
KOSPI 200
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
128940 vs KOSPI 200

Performance Gap Between 128940 and KOSPI200
HIDDEN
Show

Performance By Year
128940 vs KOSPI 200

Loading
128940
KOSPI 200
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Hanmi Pharm Co Ltd vs Peers

KOSPI 200
128940
LLY
JNJ
ROG
AZN
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Hanmi Pharm Co Ltd
Glance View

Market Cap
5.4T KRW
Industry
Pharmaceuticals

Hanmi Pharm Co., Ltd. is a remarkable player in the pharmaceutical industry hailing from South Korea, a country renowned for its technological and medical advancements. The company's journey began in 1973, and it has since carved out a substantial niche within the pharma sector by focusing on innovative research and development. Hanmi Pharm has been particularly recognized for its strong pipeline in pharmaceuticals addressing diabetes, oncology, and autoimmune diseases. It leverages its cutting-edge proprietary technology platforms such as LAPSCOVERY, which is dedicated to creating long-acting biologics, and Quantum Project, focused on novel small molecule drugs. These platforms are pivotal to Hanmi's strategy, enabling it not only to excel in creating new drugs but also to foster partnerships and licensing deals on a global scale, which constitute a significant revenue stream for the company. Beyond innovation, Hanmi Pharm has diversified its business operations across various sectors of pharmaceuticals including finished goods, active pharmaceutical ingredients (APIs), and over-the-counter (OTC) products. The company's revenue model is multifaceted and robust; it generates income by selling its pharmaceuticals in domestic and international markets and taps into significant contract manufacturing opportunities. Additionally, Hanmi Pharm has managed to establish strategic alliances with global pharmaceutical giants, resulting in lucrative licensing agreements. These collaborations allow Hanmi to not only broaden its distribution channels but also enhance its R&D capabilities by synergizing with the technological prowess of its partners. Through these multifarious routes, Hanmi Pharm has built a complex, enduring, and well-oiled machine that propels its financial growth and sustains its competitive edge within the industry.

Hanmi Pharm Co Ltd Intrinsic Value
HIDDEN
Show
Back to Top